- Home
- ENTO vs NITO Comparison
ENTO vs NITO Comparison
Compare ENTO & NITO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTO
- NITO
- Stock Information
- Founded
- ENTO 2014
- NITO 2009
- Country
- ENTO United States
- NITO Israel
- Employees
- ENTO N/A
- NITO N/A
- Industry
- ENTO Biotechnology: Pharmaceutical Preparations
- NITO
- Sector
- ENTO Health Care
- NITO
- Exchange
- ENTO Nasdaq
- NITO NYSE
- Market Cap
- ENTO 1.2M
- NITO 1.4M
- IPO Year
- ENTO 2016
- NITO N/A
- Fundamental
- Price
- ENTO $0.62
- NITO $0.28
- Analyst Decision
- ENTO
- NITO
- Analyst Count
- ENTO 0
- NITO 0
- Target Price
- ENTO N/A
- NITO N/A
- AVG Volume (30 Days)
- ENTO 924.5K
- NITO 6.4M
- Earning Date
- ENTO 10-21-2024
- NITO 11-12-2024
- Dividend Yield
- ENTO N/A
- NITO N/A
- EPS Growth
- ENTO N/A
- NITO N/A
- EPS
- ENTO N/A
- NITO N/A
- Revenue
- ENTO N/A
- NITO $166,204.00
- Revenue This Year
- ENTO N/A
- NITO N/A
- Revenue Next Year
- ENTO N/A
- NITO N/A
- P/E Ratio
- ENTO N/A
- NITO N/A
- Revenue Growth
- ENTO N/A
- NITO N/A
- 52 Week Low
- ENTO $0.19
- NITO $0.20
- 52 Week High
- ENTO $14.51
- NITO $7.55
- Technical
- Relative Strength Index (RSI)
- ENTO 59.35
- NITO 55.65
- Support Level
- ENTO $0.38
- NITO $0.21
- Resistance Level
- ENTO $0.87
- NITO $0.51
- Average True Range (ATR)
- ENTO 0.14
- NITO 0.05
- MACD
- ENTO 0.03
- NITO 0.01
- Stochastic Oscillator
- ENTO 52.57
- NITO 25.81
About ENTO Entero Therapeutics Inc. Common Stock
Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
About NITO N2OFF INC
N2OFF Inc is a pioneering agri-food tech company dedicated to developing sustainable solutions for the plant-based food industry. Operating through two subsidiaries, it delivers integrated solutions for enhanced safety, quality, and sustainability from field to fork.